Patterns of mutations in TP53 mutated AML

Abstract

TP53 mutated acute myeloid leukemia (AML) responds poorly to chemotherapy and has a short overall survival rate with a median of 5-9 months. Poor outcomes in TP53 mutated AML following chemotherapy have been observed and treatment options remain limited, although the presence of TP53 mutations alone should not be a barrier to therapy. Decitabine is emerging as an alternative treatment option for patients with TP53 mutated AML, although the agent has not been associated with deep molecular remissions and requires additional consolidation. The clinical and genomic characteristics of TP53 mutated AML are reviewed in this paper.

Keywords: AML; Acute myeloid leukemia; CHIP; Clonal hematopoiesis of indeterminate potential; Decitabine; MDS; Mutation patterns; Myelodysplastic syndromes; TP53.